| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24003 |
| Drug | Tirzepatide |
| Brand | Mounjaro® |
| Indication | Tirzepatide (Mounjaro®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes. |
| Rapid review commissioned | 24/01/2024 |
| Rapid review completed | 06/02/2024 |
| Full pharmacoeconomic assessment commissioned by HSE | 01/03/2024 |
| Pre-submission consultation with Applicant | 30/04/2024 |
| Full submission received from Applicant | 10/04/2025 |
| Assessment process on hold as updated submission required | 02/05/2025 |
| NCPE assessment recommenced | 23/08/2025 |
| Preliminary review sent to Applicant | 19/09/2025 |
| NCPE assessment recommenced | 06/11/2025 |
| Factual accuracy check sent to Applicant | 09/01/2026 |
| NCPE assessment recommenced | 16/01/2026 |
| NCPE assessment completed | 09/02/2026 |
| NCPE assessment outcome | The NCPE recommends that tirzepatide for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise (i) as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; (ii) in addition to other medicinal products for the treatment of diabetes; be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.